Faiez Zannad

Faiez Zannad is Emeritus Professor of Therapeutics at the University of Lorraine, Formerly Head of the Division of Heart Failure and Hypertension, and Director of the Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux, Nancy, France. He is a MD, cardiologist and heart failure (HF) specialist and PhD in clinical pharmacology. Eugene Braunwald Scholar, visiting Professor at Brigham & Women’s hospital, Harvard Medical School, Boston, USAin 2019. FZ has pioneered and made significant contributions to research and care in HF, such as evidence-based therapy for HF (mainly mineralocorticoid receptor antagonists and beta-blockers, SGLT2 inhibitors, Sacubutril-Valsaratn), as well as in major comorbid diseases in HF, such as sleep-disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalaemia, chronic kidney disease and thrombosis. He recently led two important European-granted HF biomarker and fibrosis programmes and is steering several ongoing major HF trials. He successfully implemented the largest HF disease management programme in France (ICALOR). He has served as Chairman of the French Society of Hypertension, Chairman of the European Society of Cardiology (ESC) Working Group on Pharmacology and Drug Therapy, and as a board member of the Heart Failure Association (HFA) of the ESC. He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think tank dedicated to the science of clinical trials, with meetings in Paris and Washington D.C. in the Middle East and Asia. Professor Zannad has published more than 950 peer-reviewed papers, several books and book chapters. He received the 2014 European Society of Hypertension Paul Milliez Award, the 2017 Lifetime Achievement Award from the ESC-HFA, and the Trophées des Etoiles of the French Ministry of Research.